CN105797193B - 一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 - Google Patents
一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 Download PDFInfo
- Publication number
- CN105797193B CN105797193B CN201610217073.5A CN201610217073A CN105797193B CN 105797193 B CN105797193 B CN 105797193B CN 201610217073 A CN201610217073 A CN 201610217073A CN 105797193 B CN105797193 B CN 105797193B
- Authority
- CN
- China
- Prior art keywords
- sensitive
- thermo
- arginine
- hydrogel
- long acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 66
- 239000004475 Arginine Substances 0.000 title claims abstract description 41
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000004964 aerogel Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000000017 hydrogel Substances 0.000 claims abstract description 75
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 51
- 235000009697 arginine Nutrition 0.000 claims abstract description 40
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 30
- 239000000178 monomer Substances 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 26
- 150000001483 arginine derivatives Chemical class 0.000 claims abstract description 25
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000011159 matrix material Substances 0.000 claims abstract description 10
- 239000012153 distilled water Substances 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229930064664 L-arginine Natural products 0.000 claims abstract description 7
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 7
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 5
- 238000004140 cleaning Methods 0.000 claims abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 22
- -1 poly (hexamethylene) hydrochloride Polymers 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 229910021529 ammonia Inorganic materials 0.000 claims description 11
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 10
- 239000004814 polyurethane Substances 0.000 claims description 8
- 229920002635 polyurethane Polymers 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- 239000003999 initiator Substances 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 229960001699 ofloxacin Drugs 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- KLZMUJRJFXYDCW-UHFFFAOYSA-N 2-[6-(diaminomethylideneamino)hexyl]guanidine;hydrochloride Chemical group Cl.NC(N)=NCCCCCCN=C(N)N KLZMUJRJFXYDCW-UHFFFAOYSA-N 0.000 claims 1
- 229920002413 Polyhexanide Polymers 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 230000036316 preload Effects 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 21
- 208000027418 Wounds and injury Diseases 0.000 abstract description 21
- 238000001179 sorption measurement Methods 0.000 abstract description 7
- 238000003756 stirring Methods 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 6
- 206010053615 Thermal burn Diseases 0.000 abstract description 2
- 230000000472 traumatic effect Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- JCVJEEJXXIFPCD-UHFFFAOYSA-N 1-methylideneguanidine;hydrochloride Chemical compound Cl.NC(=N)N=C JCVJEEJXXIFPCD-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- YICILWNDMQTUIY-UHFFFAOYSA-N 2-methylidenepentanamide Chemical compound CCCC(=C)C(N)=O YICILWNDMQTUIY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法,在水凝胶的表面及水凝胶的内部分布有抗菌药物。制备方法包括:将L‑精氨酸和碳酸氢钠溶于蒸馏水中,于0℃条件下滴加甲基丙烯酸酐,搅拌,调节溶液pH为7.4,过滤,清洗,得到改性精氨酸单体(M‑Arg);将两种抗菌药物A和B通过化学接枝和预载药的方法与N‑异丙基丙烯酰胺单体以及改性精氨酸单体结合,得到温敏性精氨酸基长效抗菌水凝胶,然后与基体结合,得到温敏性精氨酸基长效抗菌水凝胶敷料。本发明的原料具有良好的生物相容性,得到的水凝胶敷料,既有温敏性,又能够抗细菌、抗蛋白吸附,同时具有长效抗菌功能,适用于烧伤、烫伤和外伤性创伤的创面保护和治疗。
Description
技术领域
本发明属于医用材料及其制备领域,特别涉及一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法。
背景技术
伤口的愈合是一个动态的过程,而敷料的性能可以改变愈合的进展。敷料的发展经历了传统型的亚麻布、羊油脂,被动型的纱布、棉花、纱布垫,逐渐研究发明了新型的密闭性、半封闭性敷料。随着人们生活节奏的加快以及工作压力的加大,时间对大部分人越来越重要,传统型和被动型的敷料因存在无法促进伤口愈合、伤口愈合时间长,并且使用时易粘连伤口造成二次损伤、止血性不强,易感染,敷料使用量大等诸多缺点,因此新型封闭性、半封闭性敷料越来越受到人们的青睐。
常用的新型封闭性、半封闭性敷料主要有水凝胶类敷料、薄膜类敷料、泡沫型敷料、水胶体敷料和藻酸盐类敷料。虽然不同的新型敷料研究的都比较多,但或多或少有些局限性。薄膜类敷料透明便于观察伤口,但该类敷料吸水性能欠佳;泡沫类敷料富有弹性、可塑性强、轻便,但敷料不透明,难以观察创面情况;水胶体类敷料不适用于渗出液多的创面。而水凝胶敷料作为新型敷料的一种,它透明的外观便于观察伤口的愈合过程,并且能不断吸收创面渗出液,保持创面湿润、清创和加快伤口愈合,近年来得到了飞速的发展。
虽然新型封闭性、半封闭性敷料有助于细胞生长,促进伤口的愈合,但同时也有利于有害微生物的滋长,因此新型敷料的抗有害微生物感染特性就显得尤为重要。有许多研究报道了通过浸渍、涂层等方法赋予敷料抗菌或抑菌功能,从而来改善敷料的抗有害微生物性能,但是效果均不佳。
发明内容
本发明所要解决的技术问题是提供一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法,该敷料既具有温敏性,又能够抗细菌、抗蛋白吸附,同时具有长效抗菌功能。
本发明的一种温敏性精氨酸基长效抗菌水凝胶敷料,在水凝胶的表面及水凝胶的内部分布着抗菌药物;其中,水凝胶为改性精氨酸单体与N-异丙基丙烯酰胺单体共混得到。
所述水凝胶表面分布的抗菌药物为聚六亚甲基胍盐酸盐;水凝胶内部分布的抗菌药物为洗必泰或左氧氟沙星。
所述载药方法分别为化学接枝和预载药法。
本发明的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,包括:
(1)将L-精氨酸和碳酸氢钠溶于蒸馏水中,于0℃条件下滴加甲基丙烯酸酐,搅拌,调节溶液的pH为7.4,过滤,清洗,得到改性精氨酸单体;
(2)两种抗菌药物A和B通过化学接枝和预载药的方法与N-异丙基丙烯酰胺单体以及步骤(1)中的改性精氨酸单体结合,得到温敏性精氨酸基长效抗菌水凝胶;
(3)将步骤(2)中的温敏性精氨酸基长效抗菌水凝胶与基体结合,得到温敏性精氨酸基长效抗菌水凝胶敷料。
所述步骤(1)中L-精氨酸和甲基丙烯酸酐的摩尔比为1~1.2。
所述步骤(1)中pH调节方式为:通过氢氧化钠溶液;以使改性精氨酸单体上具有正负两性离子。
所述步骤(2)中抗菌药物通过化学接枝和预载药的方法与N-异丙基丙烯酰胺单体以及改性精氨酸单体结合的方法为:
将改性精氨酸单体与N-异丙基丙烯酰胺单体溶于蒸馏水中,加入微量抗菌药物A;然后加入交联剂、引发剂和催化剂,反应得到具有温敏性即药物缓释功能的水凝胶;
然后将水凝胶在活化剂的作用下与抗菌药物B进行共聚接枝,反应得到温敏性精氨酸基长效抗菌水凝胶。
所述步骤(2)中抗菌药物通过化学接枝和预载药的方法与N-异丙基丙烯酰胺单体以及改性精氨酸单体结合的方法为:
将改性精氨酸单体在活化剂的作用下溶于抗菌药物B的溶液中,反应后干燥,得到具有持久抗菌功能的水凝胶单体;
将持久抗菌功能的水凝胶单体与N-异丙基丙烯酰胺单体混合,加入微量抗菌药物A;然后加入交联剂、引发剂和催化剂,反应得到温敏性精氨酸基长效抗菌水凝胶。
所述改性精氨酸单体与N-异丙基丙烯酰胺单体的质量为1:2~2:1。
所述抗菌药物A为洗必泰或左氧氟沙星;抗菌药物B为聚六亚甲基胍盐酸盐PHMG。
所述聚六亚甲基胍盐酸盐的制备方法为:将盐酸胍和己二胺通过电动搅拌装置进行反应,在100℃下反应1h,反应产生的氨气通过导入HCl溶液进行中和,待氨气导出速度较慢时,升温至180℃,反应6h,然后冷却,搅拌均匀出料、在100℃下真空干燥后可得到广谱抗菌药物B,即聚六亚甲基胍盐酸盐。
所述步骤(3)中基体为聚氨酯。
所述的PHMG在180℃条件下反应制备时,反应时间不同,反应生成的聚合物的相对分子质量不同。
本发明的温敏性精氨酸基长效抗菌水凝胶敷料,包括聚氨酯基体和设置其上的水凝胶层,水凝胶经过交联剂作用与聚氨酯基体紧密结合在一起。本发明所使用的原料具有良好的生物相容性,通过两种不同单体比例合成的水凝胶层具有较大的吸收伤口渗出液的能力,并且制备形成的该水凝胶敷料,既具有温敏性,又能够抗细菌、抗蛋白吸附,同时具有长效抗菌功能。适用于烧伤、烫伤和外伤性创伤的创面保护和治疗。
本发明的温敏性精氨酸基长效抗菌水凝胶敷料的制备方法:以两种不同方式将两种广谱抗菌药物载入温敏型抗菌抗蛋白吸附水凝胶中,随后,将水凝胶与基体紧密结合在一起,从而制备形成具有温敏性、抗细菌抗蛋白吸附的长效抗菌水凝胶敷料。
本发明的广谱抗菌药物聚六亚甲基胍盐酸盐PHMG的制备方法:将盐酸胍和己二胺按摩尔比1:1加入到电动搅拌器中,在100℃下反应1h(反应产生的氨气导入到HCl溶液中中和),待氨气导出速度较缓时,升温至180℃,继续进行反应,反应时间不同,产物相对分子质量不同。最后停止升温,搅拌均匀出料,干燥并密封保存。
本发明的长效抗菌水凝胶敷料采用化学接枝和预载药的方法将药物接枝共聚在水凝胶的表面以及水凝胶的内部。接枝的药物可通过化学键的稳定作用将药物固定在水凝胶上,具有长效抗菌作用,而载入水凝胶内部的药物则具有缓释效果,从而减少敷料的更换频率。
本发明所采用的抗菌药物,具有广谱杀菌和抗菌的功能。由于抗菌药物均匀地接枝和分布在水凝胶中,因此具有长效稳定的抗菌功能。将制备的抗菌水凝胶敷料采用抗菌标准GB/T20944.1-2007琼脂平皿扩散法对革兰氏阳性金黄色葡萄球菌(S.aureus)和革兰氏阴性大肠杆菌(E.coli)进行抗菌对比测试,经抗菌处理的水凝胶敷料具有持久杀菌和抗菌能力。
本发明所采用的水凝胶敷料具有智能抗菌功能,通过感知温度的变化而智能缓释抗菌药物。当人体受到创伤体内温度升高时,水凝胶收缩(但仍具有较大的吸收伤口渗出液的能力),从而加快水凝胶内部药物的释放以起到杀菌治愈伤口的作用;当人体温度降低时,水凝胶溶胀,减少药物的释放,这样可以增加抗菌药物的使用效率。
本发明所采用的水凝胶敷料具有抗菌、抗蛋白吸附等功能。通过改性精氨酸使其表面带有正负两性离子,可以减少细菌的吸附以及更换敷料时因敷料与伤口粘连而造成的二次损伤,加快伤口的愈合。
本发明所采用的水凝胶单体原料为精氨酸,具有生物相容性好、易被生物酶降解的功能,通过控制水凝胶交联密度的大小及精氨酸/N-异丙基丙烯酰胺的比例可以控制水凝胶降解的速率;水凝胶敷料的基体也选用生物相容性比较好的聚氨酯,透明、亲水、透气且对人体无害。
本发明在考察对比大量医用抗菌剂的基础上,选择将聚六亚甲基胍盐酸盐接枝到水凝胶上,将洗必泰或左氧氟沙星载入水凝胶中。聚六亚甲基胍盐酸盐具有较强的杀菌能力,对细菌、病毒等有较长的作用时效。聚六亚甲基胍盐酸盐表面的氨基易与羧基发生酰胺反应从而接枝到水凝胶表面,使水凝胶敷料具有长效抗菌功效;洗必泰是一种广谱抗菌剂,杀菌范围广,性能稳定,可用于皮肤,黏膜消毒,已被广泛用作杀菌剂并用作典型的防腐剂长达30多年,主要通过吸附于细菌表面破坏细菌细胞膜致使其死亡以及抑制细菌、病毒的分裂,使细胞、病毒丧失生殖功能;左氧氟沙星是喹诺酮类药物中的一种,具有广谱抗菌作用,抗菌作用强,对多数肠杆菌科细菌,如大肠杆菌等革兰阴性菌有较强的抗菌活性,对金黄色葡萄球菌也具有较好的抗菌性能,主要是通过抑制DNA的复制导致细菌死亡。
本发明通过使用智能水凝胶作为敷料则可以通过其对外界环境的微小变化或刺激来提升药物的有效释放。
有益效果
(1)本发明的药物通过化学键的稳定作用将药物固定在水凝胶上,具有长效抗菌作用,而载入水凝胶内部的药物则具有缓释效果,从而减少敷料的更换频率;
(2)本发明的水凝胶敷料具有智能抗菌功能,通过感知温度的变化而智能缓释抗菌药物,从而增加抗菌药物的使用效率;
(3)本发明的水凝胶敷料具有抗菌、抗蛋白吸附等功能;通过改性精氨酸使其表面带有正负两性离子,可以减少细菌的吸附以及更换敷料时因敷料与伤口粘连而造成的二次损伤,加快伤口的愈合;
(4)本发明所采用的水凝胶单体原料为精氨酸,具有生物相容性好、易被生物酶降解的功能,通过控制水凝胶交联密度的大小及精氨酸/N-异丙基丙烯酰胺的比例可以控制水凝胶降解的速率;水凝胶敷料的基体也选用生物相容性比较好的聚氨酯,透明、亲水、透气且对人体无害。
附图说明
图1为实施例1中的温敏性精氨酸基长效抗菌水凝胶的合成原理图;
图2为本发明的温敏性精氨酸基长效抗菌水凝胶抗菌机理图;
图3为本发明中温敏性精氨酸基长效抗菌水凝胶敷料的结构示意图。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1
a)改性精氨酸水凝胶单体的制备:
改性精氨酸单体的制备:将0.1mol的L-精氨酸、0.2mol的碳酸氢钠以及100ml蒸馏水置于圆底烧瓶中,冷却至0℃,并往烧瓶中逐滴滴加0.12mol的甲基丙烯酸酐,搅拌1.5h后,以氢氧化钠稀溶液调节溶液pH=7.4。随后过滤并用CH2Cl2洗三遍除去杂质以及未反应的原料,最后在-50℃及真空下冻干得到白色粉末固体,即为改性精氨酸单体(M-Arg)。
b)广谱抗菌药物聚六亚甲基胍盐酸盐的制备:
将盐酸胍和己二胺按摩尔比1:1加入到电动搅拌器中,在100℃下反应1h(反应产生的氨气导入到HCl溶液中中和),待氨气导出速度较缓时,升温至180℃,继续进行反应6h,最后停止升温,搅拌均匀出料,在100℃下真空干燥并密封保存。
c)具有温敏性且持久抗菌功能水凝胶的制备:
首先制备改性精氨酸单体,之后与N-异丙基丙烯酰胺单体及广谱抗菌药物经共混合成具有温敏性且持久抗菌功能的水凝胶:取改性精氨酸单体与N-异丙基丙烯酰胺单体共0.1g(质量比为:1:2)及2mg洗必泰溶于2mL去离子水中,以BIS为交联剂,APS为引发剂的条件下,再加入0.06g催化剂TEMED,在室温下反应20~30min即形成具有温敏性及药物缓释功能的水凝胶1;将制备的水凝胶1放置在聚六亚甲基胍盐酸盐溶液中(1.917gEDC,1.1509gNHS,5g聚六亚甲基胍盐酸盐,1mL三乙胺,20mL蒸馏水),在活化剂EDC和NHS的作用下,水凝胶1上的羧基与聚六亚甲基胍盐酸盐上的氨基发生酰胺发生反应,从而使具有广谱抗菌作用的聚六亚甲基胍盐酸盐接枝固定在水凝胶1上,即形成具有温敏性且持久抗菌功能的水凝胶2。按此比例得到的水凝胶最低临界温度为37℃,溶胀率高达2500%,经过抗菌实验证明,在抗菌实验进行到第10天后,该水凝胶仍具有良好的抗大肠杆菌和金黄色葡萄球菌的能力。
d)具有温敏性且持久抗菌水凝胶敷料的制备:
按照b所述制作形成一块4cm*4cm的平板水凝胶,将平板水凝胶通过明胶的粘结作用置于聚氨酯透明薄膜上,将平板水凝胶与聚氨酯薄膜紧密结合从而制备形成具有温敏性且持久抗菌水凝胶敷料。
实施例2
a)具有持久抗菌功能的水凝胶单体的制备:
改性精氨酸单体的制备:将0.1mol的L-精氨酸、0.2mol的碳酸氢钠以及100ml蒸馏水置于圆底烧瓶中,冷却至0℃,并往烧瓶中逐滴滴加0.12mol的甲基丙烯酸酐,搅拌1.5h后,以氢氧化钠稀溶液调节溶液pH=7.4。随后过滤并用CH2Cl2洗三遍除去杂质以及未反应的原料,最后在-50℃及真空下冻干得到白色粉末固体,即为改性精氨酸单体。
将盐酸胍和己二胺按摩尔比1:1加入到电动搅拌器中,在100℃下反应1h(反应产生的氨气导入到HCl溶液中中和),待氨气导出速度较缓时,升温至180℃,继续进行反应6h,最后停止升温,搅拌均匀出料,在100℃下真空干燥并密封保存,即得到广谱抗菌药物聚六亚甲基胍盐酸盐。
将0.1g改性精氨酸单体溶解于具有广谱抗菌作用的聚六亚甲基胍盐酸盐的溶液(1.917gEDC,1.1509gNHS,5g聚六亚甲基胍盐酸盐,1mL三乙胺,20mL蒸馏水)中,使改性精氨酸单体上的羧基与聚六亚甲基胍盐酸盐的氨基发生酰胺发应,然后冻干干燥,从而形成具有持久抗菌功能的水凝胶单体。
b)具有温敏性且持久抗菌功能水凝胶的制备:
将制备的具有持久抗菌功能的水凝胶单体与N-异丙基丙烯酰胺单体及广谱抗菌药物合成具有温敏性且持久抗菌功能的水凝胶:取具有持久抗菌功能的精氨酸单体与N-异丙基丙烯酰胺单体(质量比为1:2)及2mg洗必泰,以BIS为交联剂,APS为引发剂的条件下,最后加入0.06g催化剂TEMED,在室温下反应20~30min即形成具有温敏性及持久抗菌功能的水凝胶。
c)具有温敏性且持久抗菌水凝胶敷料的制备:
按照b所述制作形成一块4cm*4cm的平板水凝胶,将平板水凝胶通过明胶的粘结作用置于聚氨酯透明薄膜上,将平板水凝胶与聚氨酯薄膜紧密结合从而制备形成具有温敏性且持久抗菌水凝胶敷料。
Claims (10)
1.一种温敏性精氨酸基长效抗菌水凝胶敷料,其特征在于,在水凝胶的表面及水凝胶的内部分布有抗菌药物;其中,水凝胶为改性精氨酸单体与N-异丙基丙烯酰胺单体在交联剂、引发剂和催化剂的作用下通过共混得到,水凝胶表面分布的抗菌药物为聚六亚甲基胍盐酸盐。
2.根据权利要求1所述的一种温敏性精氨酸基长效抗菌水凝胶敷料,其特征在于,所述水凝胶内部分布的抗菌药物为洗必泰或左氧氟沙星。
3.一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,包括:
(1)将L-精氨酸和碳酸氢钠溶于蒸馏水中,于0℃条件下滴加甲基丙烯酸酐,搅拌,调节溶液的pH为7.4,过滤,清洗,得到改性精氨酸单体;
(2)将两种抗菌药物A和B通过预载药和化学接枝的方法与N-异丙基丙烯酰胺单体以及步骤(1)中的改性精氨酸单体结合,得到温敏性精氨酸基长效抗菌水凝胶,抗菌药物B为聚六亚甲基胍盐酸盐;
(3)将步骤(2)中的温敏性精氨酸基长效抗菌水凝胶与基体结合,得到温敏性精氨酸基长效抗菌水凝胶敷料。
4.根据权利要求3所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述步骤(1)中L-精氨酸和甲基丙烯酸酐的摩尔比为1:1.2。
5.根据权利要求3所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述步骤(2)中将两种抗菌药物A和B通过预载药和化学接枝的方法与N-异丙基丙烯酰胺单体以及步骤(1)中的改性精氨酸单体结合的方法为:
将改性精氨酸单体与N-异丙基丙烯酰胺单体溶于蒸馏水中,加入抗菌药物A;然后加入交联剂、引发剂和催化剂,反应得到具有温敏性药物缓释功能的水凝胶;
然后将水凝胶在活化剂的作用下与抗菌药物B进行共聚接枝,反应得到温敏性精氨酸基长效抗菌水凝胶。
6.根据权利要求3所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述步骤(2)中将两种抗菌药物A和B通过预载药和化学接枝的方法与N-异丙基丙烯酰胺单体以及步骤(1)中的改性精氨酸单体结合的方法为:
将改性精氨酸单体在活化剂的作用下溶于抗菌药物B的溶液中,反应后干燥,得到具有持久抗菌功能的水凝胶单体;
将持久抗菌功能的水凝胶单体与N-异丙基丙烯酰胺单体混合,加入抗菌药物A;然后加入交联剂、引发剂和催化剂,反应得到温敏性精氨酸基长效抗菌水凝胶。
7.根据权利要求5或6所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述改性精氨酸单体与N-异丙基丙烯酰胺单体的质量为1:2~2:1。
8.根据权利要求5或6所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述抗菌药物A为洗必泰或左氧氟沙星。
9.根据权利要求8所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述聚六亚甲基胍盐酸盐的制备方法为:将盐酸胍和己二胺在搅拌条件下,于100℃下反应1h,反应产生的氨气通过导入HCl溶液进行中和,然后升温至180℃,反应6h,冷却,搅拌均匀出料,干燥,得到广谱抗菌药物B,即聚六亚甲基胍盐酸盐。
10.根据权利要求3所述的一种温敏性精氨酸基长效抗菌水凝胶敷料的制备方法,其特征在于,所述步骤(3)中基体为聚氨酯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610217073.5A CN105797193B (zh) | 2016-04-08 | 2016-04-08 | 一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610217073.5A CN105797193B (zh) | 2016-04-08 | 2016-04-08 | 一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105797193A CN105797193A (zh) | 2016-07-27 |
CN105797193B true CN105797193B (zh) | 2018-12-04 |
Family
ID=56459688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610217073.5A Expired - Fee Related CN105797193B (zh) | 2016-04-08 | 2016-04-08 | 一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105797193B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279575A (zh) * | 2016-08-17 | 2017-01-04 | 林春梅 | 一种温敏型复合水凝胶及其制备方法 |
CN106727669A (zh) * | 2016-10-21 | 2017-05-31 | 苏州度博迈医疗科技有限公司 | 一种高效温和的皮肤消毒凝胶及其制备方法 |
CN106832347B (zh) * | 2017-02-24 | 2019-03-08 | 东华大学 | 一种安全高效持久抗菌纳米水凝胶及其制备方法 |
CN107815871B (zh) * | 2017-11-24 | 2020-01-14 | 东华大学 | 一种持久抗菌织物的制备方法 |
CN109503832A (zh) * | 2018-10-18 | 2019-03-22 | 上海高聚生物科技有限公司 | 一种聚环氧丙基己基胍盐酸盐及其制备方法 |
CN112618785B (zh) * | 2020-12-15 | 2022-07-01 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种多孔抗菌水凝胶敷料及其制备方法 |
CN112695411B (zh) * | 2020-12-28 | 2022-07-01 | 浙江理工大学 | 一种温度响应型纳米纤维敷料的制备方法 |
CN113230205B (zh) * | 2021-05-22 | 2023-07-07 | 绍兴鸿瑞生物科技有限公司 | 一种妇科凝胶制剂及其制备方法和应用 |
CN113769177B (zh) * | 2021-08-26 | 2022-05-27 | 四川大学 | 一种可降解封堵器涂层及其制备方法 |
CN113999406B (zh) * | 2021-11-08 | 2023-07-28 | 河北工业大学 | 一种多功能抗菌水凝胶敷料的制备方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1844170A (zh) * | 2006-04-24 | 2006-10-11 | 天津大学 | 温敏聚异丙基丙烯酰胺-聚精氨酸缀合物转基因载体的制备 |
CN101024697A (zh) * | 2007-02-05 | 2007-08-29 | 中国科学院长春应用化学研究所 | 聚n-异丙基丙烯酰胺-聚氨基酸两嵌段共聚物及制备方法 |
KR100868724B1 (ko) * | 2007-05-30 | 2008-11-13 | 한국생산기술연구원 | 가역적 온도감응성을 가지는 자기집합성 나노운반체의제조방법 |
WO2009126441A1 (en) * | 2008-04-10 | 2009-10-15 | Board Of Regents, The University Of Texas System | Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles |
-
2016
- 2016-04-08 CN CN201610217073.5A patent/CN105797193B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1844170A (zh) * | 2006-04-24 | 2006-10-11 | 天津大学 | 温敏聚异丙基丙烯酰胺-聚精氨酸缀合物转基因载体的制备 |
CN101024697A (zh) * | 2007-02-05 | 2007-08-29 | 中国科学院长春应用化学研究所 | 聚n-异丙基丙烯酰胺-聚氨基酸两嵌段共聚物及制备方法 |
KR100868724B1 (ko) * | 2007-05-30 | 2008-11-13 | 한국생산기술연구원 | 가역적 온도감응성을 가지는 자기집합성 나노운반체의제조방법 |
WO2009126441A1 (en) * | 2008-04-10 | 2009-10-15 | Board Of Regents, The University Of Texas System | Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles |
Non-Patent Citations (1)
Title |
---|
A novel composite matrix based on polymeric micelle and hydrogel as a drug carrier for the controlled release of dual drugs;T.S.Anirudhan et al;《Carbohydrate Polymers》;20151012;第136卷;1118-1127 * |
Also Published As
Publication number | Publication date |
---|---|
CN105797193A (zh) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105797193B (zh) | 一种温敏性精氨酸基长效抗菌水凝胶敷料及其制备方法 | |
US10973691B2 (en) | Composition for a wound dressing | |
ES2944592T3 (es) | Composición para un apósito para heridas | |
Singh et al. | Radiation synthesis of PVP/alginate hydrogel containing nanosilver as wound dressing | |
RU2748124C2 (ru) | Композиция для раневых повязок | |
CN110152051B (zh) | 一种吸水烧创伤抗菌敷料及其制备方法和用途 | |
CN106832347B (zh) | 一种安全高效持久抗菌纳米水凝胶及其制备方法 | |
RU149063U1 (ru) | Повязка для заживления ран с противомикробным действием | |
CN102675651B (zh) | 抗菌敷料用壳聚糖水凝胶的制备方法 | |
CN105288704B (zh) | 一种聚酰胺-胺树形分子改性壳聚糖创面修复水凝胶及其制备方法和应用 | |
CN110028614A (zh) | 具有蛋白吸附功能的抗菌微纳米凝胶与纤维及其制备方法 | |
CN111643720A (zh) | 一种具有抗菌性能的烧伤创面愈合用水凝胶及其制备方法 | |
CN108484936A (zh) | 一种接枝改性材料所制备的水凝胶及其制备方法和应用 | |
Parwani et al. | Gum acacia-PVA hydrogel blends for wound healing | |
CN112587717A (zh) | 一种金属阳离子交联海藻酸盐/细菌纤维素复合水凝胶抗菌敷料 | |
CN104857550B (zh) | 一种ε‑聚赖氨酸‑对羟基苯丙酸抗菌水凝胶敷料及其制备方法 | |
CN113509591A (zh) | 一种抗菌阳离子可注射水凝胶敷料及其制备方法 | |
Singh et al. | Radiation synthesis of hydrogels with silver nanoparticles for use as an antimicrobial burn wound dressing | |
CN115624647A (zh) | 一种复合创口愈合药物与膜精华液的生物膜医用敷料及其制备方法和应用 | |
CN100488572C (zh) | 磺胺嘧啶盐高分子水凝胶敷料及其制备方法 | |
CN115414523B (zh) | 一种水凝胶敷料及其制备方法 | |
Zheng et al. | Preparation and Hemostatic Effect of Micro-Nanograded Porous Particles Doped with Dopamine-Based Water-Triggered Intelligent Composite Adhesives | |
CN115300666B (zh) | 一种生物启发协同抗菌水凝胶敷料及其制备方法 | |
RU2775940C2 (ru) | Композиция для раневых повязок | |
Yang et al. | pH-Responsive Medical Dressing Based on Zinc Sulfide Nanoparticle/Silk Fibroin Composite Fibers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181204 |